Endo Claims Teva, Others Infringe Uncrushable Opana IP

Law360, Chicago (May 16, 2013, 3:43 PM EDT) -- Endo Pharmaceuticals Inc. on Wednesday targeted Teva Pharmaceuticals Industries Inc., Par Pharmaceutical Inc., Mallinckrodt LLC and others with patent infringement lawsuits in New York aimed at blocking generic drugs that would compete with the crush-resistant version of its Opana ER painkiller.

In complaints against Teva, Par, Mallinckrodt, Sandoz Inc., Roxane Laboratories Inc. and Barr Laboratories Inc., the plaintiff alleges the defendants' commercial manufacture, distribution use and sale of generic extended release oxymorphone hydrochloride tablets would infringe three of Endo's patents.

According to the plaintiff, while Endo...
To view the full article, register now.